ARVN
What one share of Arvinas holds
Pharmaceutical Preparations
We are a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through our PROteolysis TArgeting Chimera, or PROTAC, protein degradation platform, we are pioneering the development of a new class of therapeutics designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.
Arvinas’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $4.71 |
|---|---|
| Profit | $0.14 |
| Capex (buildings and equipment) | $0.03 |
| Free cash flow | −$3.10 |
| Cash and investments | $8.70 |
| Debt | $0.01 |
| Book value | $8.61 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | $3.99 | −$15.08 | $0.53 | $2.16 | — | −$32.27 |
| 2018 | $1.52 | −$25.45 | $0.30 | −$2.01 | — | — |
| 2019 | $1.31 | −$2.14 | $0.19 | −$1.43 | — | $5.89 |
| 2020 | $0.66 | −$3.02 | $0.16 | −$2.43 | — | $13.24 |
| 2021 | $1.07 | −$3.82 | $0.09 | $11.09 | — | $14.75 |
| 2022 | $2.47 | −$5.31 | $0.13 | −$5.27 | — | $10.62 |
| 2023 | $1.41 | −$6.62 | $0.05 | −$6.32 | — | $9.71 |
| 2024 | $3.66 | −$2.77 | $0.03 | −$3.63 | — | $8.16 |
| 2025 | $3.70 | −$1.14 | $0.03 | −$3.89 | — | $6.83 |